William Dai
SlowingNamed in filings at ShangBay CapitalOn the current fund
- Board seats filed
- 11
Named in filings at ShangBay CapitalOn the current fund
all filings on record
last 24 months
from a verified or cited source
| Rila Therapeutics | Biotech & pharma | December 2024 | None on file |
| Laplace Interventional | Medical devices | July 2023 | None on file |
| Early Bird Medical | Medical devices | December 2022 | None on file |
| LUMINOPIA | Digital health | October 2022 | Kendall Capital Partners, U.S Venture Partners |
| YOR LABS | Medical devices | October 2021 | KSN |
| SetPoint Medical | Medical devices | October 2020 | Flare Capital, NEA |
| Emboline | Medical devices | August 2020 | None on file |
| Aqua Medical | Medical devices | July 2020 | None on file |
| Huma.AI | Digital health | August 2019 | Excelerate Health Ventures, Hatteras Venture Partners |
| Apostle | Biotech & pharma | May 2019 | None on file |
| NeuroVasc Technologies | Medical devices | November 2015 | None on file |
The company and date are what the SEC filing shows, not a statement of investment thesis. A partner can sit on a board for reasons that say nothing about what their firm funds today. The sector is not a filing value: it is Lev’s own classification of each company, shown only when we found a specific, checkable source for it; otherwise it reads “Not yet classified.” “Also on the board from” names another tracked firm with a partner on the same board, both with a clean identity match. It is not a claim either firm led or co-led the round, and “None on file” means no other tracked firm’s partner shares this specific board seat, not that no one else invested. Sorted newest first by default; click a column to change it. Something wrong? Tell us.
Classified sectors of companies where filings name William Dai on the board, based on 11 filed seats with a verified or cited source.